within Pharmacolibrary.Drugs.ATC.L;

model L01DB10
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0006816666666666667,
    adminDuration  = 600,
    adminMass      = 40 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.054,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.111,
    k12             = 80.0,
    k21             = 80.0
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01DB10</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Amrubicin is a synthetic anthracycline antitumor agent used in the treatment of small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). It acts primarily as a topoisomerase II inhibitor. Amrubicin is approved for use in some countries, such as Japan, primarily for lung cancer treatment.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters were assessed in adult Japanese patients with advanced non-small cell lung cancer and small cell lung cancer following intravenous administration.</p><h4>References</h4><ol><li><p>Hamada, A (2005). [Development of an individualized therapy for establishing the optimal dosage by the pharmacokinetics profiles of anticancer agents]. <i>Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan</i> 125(8) 631–637. DOI:<a href=\"https://doi.org/10.1248/yakushi.125.631\">10.1248/yakushi.125.631</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/16079613/\">https://pubmed.ncbi.nlm.nih.gov/16079613</a></p></li><li><p>Yanaihara, T, et al., &amp; Masuda, N (2007). Phase I and pharmacologic study of irinotecan and amrubicin in advanced non-small cell lung cancer. <i>Cancer chemotherapy and pharmacology</i> 59(4) 419–427. DOI:<a href=\"https://doi.org/10.1007/s00280-006-0279-5\">10.1007/s00280-006-0279-5</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/16832665/\">https://pubmed.ncbi.nlm.nih.gov/16832665</a></p></li><li><p>Okamoto, I, et al., &amp; Saito, H (2006). Phase I and pharmacokinetic study of amrubicin, a synthetic 9-aminoanthracycline, in patients with refractory or relapsed lung cancer. <i>Cancer chemotherapy and pharmacology</i> 57(3) 282–288. DOI:<a href=\"https://doi.org/10.1007/s00280-005-0051-2\">10.1007/s00280-005-0051-2</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/16028099/\">https://pubmed.ncbi.nlm.nih.gov/16028099</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01DB10;
